News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Theracos, Inc. Reports Positive Outcomes From A 96-Week Phase 2 Study Of THR1442, A Highly Specific SGLT2 Inhibitor, For The Treatment Of Type 2 Diabetes



3/17/2014 9:17:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Theracos, Inc., www.theracos.com , a privately held biotechnology company located in Marlborough, Massachusetts, today announced the results of a multinational 96-week Phase 2 study evaluating the efficacy and safety of the SGLT-2 inhibitor THR1442. The double-blinded, placebo-controlled study enrolled a total of 288 subjects with Type 2 diabetes from sites in the US, Mexico and Colombia and evaluated the efficacy of THR1442 compared to placebo as a monotherapy for the treatment of diabetes.

Help employers find you! Check out all the jobs and post your resume

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES